Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Imine Reductase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120758580A reveals enzymatic route for (S)-chiral amines. High ee value, mild conditions. Reliable supplier for pharma intermediates.
Patent CN116286700B reveals enhanced imine reductase mutants for nicotine synthesis offering superior yield and supply chain reliability for global pharmaceutical manufacturers.
Patent CN120574796A enables high-purity (S)-nornicotine production. Discover cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Patent CN116024284A reveals mutant imine reductase for S-nicotine. Achieve >99% ee and high conversion. Reliable pharmaceutical intermediate supplier for cost reduction.
Patent CN119823959B reveals novel imine reductase mutants for high-purity chiral amine synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN115948360B reveals high-efficiency biocatalytic route for neurodegenerative drug intermediates with superior stereoselectivity and scalable production potential.
Patent CN118909993A reveals a high-activity imine reductase mutant for green synthesis. Achieves >99% optical purity and high space-time yield for reliable supply.
Patent CN112852771A details enzymatic synthesis of chiral amino alcohols using imine reductase, offering high stereoselectivity and mild conditions for pharmaceutical manufacturing.
Patent CN115404249A reveals a novel enzymatic route for (S)-nicotine intermediates. Discover cost-effective biocatalysis solutions for scalable pharmaceutical manufacturing.
High-purity chiral amine intermediate for levopraziquantel. Enzymatic process ensures cost reduction and supply reliability for pharmaceutical manufacturing.
Patent CN107384885B reveals enzymatic synthesis of chiral amines. Achieve cost reduction in API manufacturing with high conversion and optical purity.
Patent CN115948360A details an imine reductase mutant achieving >99.5% conversion and 99.6% ee for nicotine analog intermediates, offering significant cost and supply chain advantages.
Patent CN117887739A reveals enzymatic route for moxifloxacin intermediate offering cost reduction and high purity for pharmaceutical manufacturing supply chains.
High-yield imine reductase method for ephedrine production offers supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN111057729B reveals enzymatic synthesis for high-purity Larotrectinib intermediates. Discover cost-effective, scalable biocatalytic manufacturing solutions.
Patent CN111057729A details a green enzymatic route for Larotretinib intermediates, offering high ee values and cost reduction in API manufacturing.
Patent CN118374465B reveals enzymatic route for (S)-nicotine. Achieves 99.1% ee value. Offers scalable biocatalysis for reliable pharmaceutical intermediates supplier chains.
Novel enzyme process for chiral amine intermediate. High purity, mild conditions, scalable for pharma manufacturing.
Patent CN112795603B reveals a high-efficiency IRED method for chiral pyrrolidines, offering superior purity and green manufacturing advantages.
Patent CN114381441B reveals imine reductase catalysis for optical pure chiral amino alcohols. Offers mild conditions and high stereoselectivity for pharmaceutical supply chains.